AZ-LIMELIGHT-NETWORKS
12.9.2019 15:38:10 CEST | Business Wire | Press release
Limelight Networks, Inc. (Nasdaq: LLNW) , a leading provider of edge cloud services, will introduce new enhancements to its Video Delivery Services at IBC 2019 that further improve the quality and performance of digital experiences for customers worldwide.
Limelight’s realtime, live and on-demand video delivery services integrate its industry-leading global private network with advanced video delivery and management capabilities, providing live and VOD media management, packaging, and delivery of broadcast-quality video to virtually any screen. Limelight holds a leader position in the IDC MarketScape: Worldwide Commercial CDN 2019 Vendor Assessment (#US44842119) on worldwide content delivery networks for its global private network, edge services, low latency video streaming capabilities, and integrated video platform. Limelight will be demonstrating low latency streaming and highlighting edge services for video applications at IBC 2019 in Hall 5 B52.
New features and enhancements to be announced at IBC 2019 include:
- Limelight has expanded its global network to almost 50Tbps of egress capacity and its edge server capacity by more than 40 percent since January. This increased capacity combined with quality-focused software improvements ensures critical quality metrics such as rebuffer rate, startup time, and bitrate viewed are improved when using Limelight’s Content Delivery Network (CDN) for live and on-demand video delivery.
- Limelight added enhancements to Realtime Streaming including Adaptive Bit Rate (ABR) support which provides the highest picture quality based on each viewer’s network conditions, and Real-Time Messaging Protocol (RTMP) fallback for devices that do not support WebRTC.
- Limelight will be adding Live Push Ingest (LPI) for live streaming over HTTP which allows customers to send their packaged HLS and DASH streams directly to the Limelight CDN for onwards delivery to the end user. LPI ensures that customers have complete control over their live stream packaging workflow and bandwidth, including stream monitoring and traffic reporting.
- The company also made updates to its Limelight Video Platform including a new HTML user interface with additional ease-of-use features such as drag and drop to manage video assets, an HTML5 video player that can be customized to match a company’s branding look and feel, and expanded player analytics on rebuffer rates and viewer engagement statistics.
“Limelight’s realtime, live and on-demand video delivery services help companies achieve their most strategic business objectives. We’re continuously building out our private global network and innovating in low latency video and edge solutions to minimize latencies and enable highly interactive applications,” said Steve Miller-Jones , Vice President, Product Strategy at Limelight Networks.
About Limelight
Limelight Networks, Inc. (NASDAQ: LLNW), a leading provider of digital content delivery, video, cloud security, and edge computing services, empowers customers to provide exceptional digital experiences. Limelight’s edge services platform includes a unique combination of global private infrastructure, intelligent software, and expert support services that enable current and future workflows. For more information, visit www.limelight.com
, follow us on Twitter
, Facebook
, and LinkedIn
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190912005576/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom